SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ehsaan Akhtar, Vignan Manne, Sammy Saab, Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis, Liver International, 2014, 34, 10
  2. 2
    Carla Krueger, Mark Collister, Gerald Y. Minuk, Alyssa Janke, Jordyn Lerner, Stephen G. M. Wong, Julia D. Rempel, HCV protein-induced cytokine predicts treatment outcomes in chronic hepatitis C virus infection, Liver International, 2014, 34, 6
  3. 3
    Mitchell L. Shiffman, Hepatitis C virus therapy in the direct acting antiviral era, Current Opinion in Gastroenterology, 2014, 30, 3, 217

    CrossRef

  4. You have free access to this content4
    Vincenzo Boccaccio, Savino Bruno, Management of HCV patients with cirrhosis with direct acting antivirals, Liver International, 2014, 34,
  5. 5
    Kazuaki Chayama, Fukiko Mitsui, C Nelson Hayes, Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection, Expert Review of Gastroenterology & Hepatology, 2014, 1

    CrossRef

  6. 6
    Victoria Belousova, Ahmed A. Abd-Rabou, Shaker A. Mousa, Recent advances and future directions in the management of hepatitis C infections, Pharmacology & Therapeutics, 2014,

    CrossRef

  7. 7
    John M. Vierling, Stefan Zeuzem, Fred Poordad, Jean-Pierre Bronowicki, Michael P. Manns, Bruce R. Bacon, Rafael Esteban, Steven L. Flamm, Paul Y. Kwo, Lisa D. Pedicone, Weiping Deng, Frank J. Dutko, Mark J. DiNubile, Kenneth J. Koury, Frans A. Helmond, Janice Wahl, Savino Bruno, Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials, Journal of Hepatology, 2014, 61, 2, 200

    CrossRef

  8. 8
    A. J. Meer, B. J. Veldt, J. J. Feld, H. Wedemeyer, J.-F. Dufour, F. Lammert, A. Duarte-Rojo, M. P. Manns, S. Zeuzem, W. P. Hofmann, R. J. Knegt, B. E. Hansen, H. L. A. Janssen, The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection, Journal of Viral Hepatitis, 2014, 21, 8
  9. 9
    S. Bruno, S. Bollani, A. L. Zignego, J. M. Pascasio, C. Magni, A. Ciancio, M. Caremani, A. Mangia, S. Marenco, S. Piovesan, L. Chemello, S. Babudieri, A. Moretti, F. Gea, C. Colletta, R. Perez-Alvarez, X. Forns, J. R. Larrubia, J. Arenas, J. Crespo, V. Calvaruso, F. Ceccherini Silberstein, P. Maisonneuve, A. Craxì, J. L. Calleja, Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program, Journal of Viral Hepatitis, 2014, 21, 12
  10. 10
    Nasser Ebrahimi Daryani, Seyed Moayed Alavian, Mohammad Hossein Somi, Mohammad Torabi-Nami, Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013, Hepatitis Monthly, 2013, 13, 11

    CrossRef

  11. 11
    Roberta D’Ambrosio, Massimo Colombo, Safety of direct antiviral agents in real life, Digestive and Liver Disease, 2013, 45, S363

    CrossRef

  12. 12
    Maribel Rodríguez-Torres, Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection, Expert Review of Anti-infective Therapy, 2013, 11, 12, 1269

    CrossRef

  13. 13
    Eric Lawitz, Alessandra Mangia, David Wyles, Maribel Rodriguez-Torres, Tarek Hassanein, Stuart C. Gordon, Michael Schultz, Mitchell N. Davis, Zeid Kayali, K. Rajender Reddy, Ira M. Jacobson, Kris V. Kowdley, Lisa Nyberg, G. Mani Subramanian, Robert H. Hyland, Sarah Arterburn, Deyuan Jiang, John McNally, Diana Brainard, William T. Symonds, John G. McHutchison, Aasim M. Sheikh, Zobair Younossi, Edward J. Gane, Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, New England Journal of Medicine, 2013, 368, 20, 1878

    CrossRef

  14. 14
    Paul M. Trembling, Sudeep Tanwar, William M. Rosenberg, Geoffrey M. Dusheiko, Treatment decisions and contemporary versus pending treatments for hepatitis C, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 12, 713

    CrossRef